Cargando…
Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies
Peritoneal carcinomatosis (PC) is a poor prognostic factor for all malignancies. This extent of metastatic disease progression remains difficult to treat with systemic therapies due to poor peritoneal vascularization resulting in limited drug delivery and penetration into tissues. Cytoreductive surg...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143396/ https://www.ncbi.nlm.nih.gov/pubmed/35628966 http://dx.doi.org/10.3390/jcm11102840 |
_version_ | 1784715796194263040 |
---|---|
author | Harper, Megan M. Kim, Joseph Pandalai, Prakash K. |
author_facet | Harper, Megan M. Kim, Joseph Pandalai, Prakash K. |
author_sort | Harper, Megan M. |
collection | PubMed |
description | Peritoneal carcinomatosis (PC) is a poor prognostic factor for all malignancies. This extent of metastatic disease progression remains difficult to treat with systemic therapies due to poor peritoneal vascularization resulting in limited drug delivery and penetration into tissues. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are surgical interventions that directly target peritoneal tumors and have improved outcomes for PC resulting from appendiceal and colorectal cancer (CRC). Despite these radical therapies, long-term survival remains infrequent, and recurrence is common. The reasons for these outcomes are multifactorial and signal the need for the continued development of novel therapeutics, techniques, and approaches to improve outcomes for these patients. Here, we review landmark historical studies that serve as the foundation for current recommendations, recent discoveries, clinical trials, active research, and areas of future interest in CRS/HIPEC to treat PC originating from appendiceal and colorectal malignancies. |
format | Online Article Text |
id | pubmed-9143396 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91433962022-05-29 Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies Harper, Megan M. Kim, Joseph Pandalai, Prakash K. J Clin Med Review Peritoneal carcinomatosis (PC) is a poor prognostic factor for all malignancies. This extent of metastatic disease progression remains difficult to treat with systemic therapies due to poor peritoneal vascularization resulting in limited drug delivery and penetration into tissues. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are surgical interventions that directly target peritoneal tumors and have improved outcomes for PC resulting from appendiceal and colorectal cancer (CRC). Despite these radical therapies, long-term survival remains infrequent, and recurrence is common. The reasons for these outcomes are multifactorial and signal the need for the continued development of novel therapeutics, techniques, and approaches to improve outcomes for these patients. Here, we review landmark historical studies that serve as the foundation for current recommendations, recent discoveries, clinical trials, active research, and areas of future interest in CRS/HIPEC to treat PC originating from appendiceal and colorectal malignancies. MDPI 2022-05-18 /pmc/articles/PMC9143396/ /pubmed/35628966 http://dx.doi.org/10.3390/jcm11102840 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Harper, Megan M. Kim, Joseph Pandalai, Prakash K. Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies |
title | Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies |
title_full | Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies |
title_fullStr | Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies |
title_full_unstemmed | Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies |
title_short | Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies |
title_sort | current trends in cytoreductive surgery (crs) and hyperthermic intraperitoneal chemotherapy (hipec) for peritoneal disease from appendiceal and colorectal malignancies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143396/ https://www.ncbi.nlm.nih.gov/pubmed/35628966 http://dx.doi.org/10.3390/jcm11102840 |
work_keys_str_mv | AT harpermeganm currenttrendsincytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecforperitonealdiseasefromappendicealandcolorectalmalignancies AT kimjoseph currenttrendsincytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecforperitonealdiseasefromappendicealandcolorectalmalignancies AT pandalaiprakashk currenttrendsincytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecforperitonealdiseasefromappendicealandcolorectalmalignancies |